Nanobiotix S.A.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Accelerated filer
State of Incorporation
France
Business Address
60 RUE DE WATTIGNIES, PARIS, I0, 75012
Mailing Address
60 RUE DE WATTIGNIES, PARIS, I0, 75012
Phone
33140260470
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 20-F Foreign company annual report | March 31, 2026 | View on SEC |
| 6-K Foreign company current report | March 31, 2026 | View on SEC |
| 6-K Foreign company current report | March 30, 2026 | View on SEC |
| 6-K Foreign company current report | March 26, 2026 | View on SEC |
| 6-K Foreign company current report | March 25, 2026 | View on SEC |
| 6-K Foreign company current report | March 12, 2026 | View on SEC |
| 6-K Foreign company current report | February 25, 2026 | View on SEC |
| 6-K Foreign company current report | December 17, 2025 | View on SEC |
| 6-K Foreign company current report | December 15, 2025 | View on SEC |
| 6-K Foreign company current report | December 1, 2025 | View on SEC |
Annual Reports
20-F
March 31, 2026
- Flagship radioenhancer NBTXR3 shows potential to transform solid tumor treatment.
- Strategic $1.8 billion partnership with Janssen Pharmaceutica validates technology.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.